GDC-0879 (BioDeep_00000743416)

   


代谢物信息卡片


(E)-5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime

化学式: C19H18N4O2 (334.1429688)
中文名称: GDC-0879
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CC(=NO)C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO
InChI: InChI=1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2/b22-18+

描述信息

GDC-0879 is a potent and selective B-Raf inhibitor with an IC50 of 0.13 nM.

同义名列表

3 个代谢物同义名

(E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime; GDC-0879; (E)-5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Eriene-Heidi Sidhom, Choah Kim, Maria Kost-Alimova, May Theng Ting, Keith Keller, Julian Avila-Pacheco, Andrew Jb Watts, Katherine A Vernon, Jamie L Marshall, Estefanía Reyes-Bricio, Matthew Racette, Nicolas Wieder, Giulio Kleiner, Elizabeth J Grinkevich, Fei Chen, Astrid Weins, Clary B Clish, Jillian L Shaw, Catarina M Quinzii, Anna Greka. Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ-deficiency kidney disease. The Journal of clinical investigation. 2021 03; 131(5):. doi: 10.1172/jci141380. [PMID: 33444290]
  • Jonas Sieber, Nicolas Wieder, Abbe Clark, Manuel Reitberger, Sofia Matan, Jeannine Schoenfelder, Jianming Zhang, Anna Mandinova, Joshua Adam Bittker, Juan Gutierrez, Ozan Aygün, Namrata Udeshi, Steven Carr, Peter Mundel, Andreas Werner Jehle, Anna Greka. GDC-0879, a BRAFV600E Inhibitor, Protects Kidney Podocytes from Death. Cell chemical biology. 2018 02; 25(2):175-184.e4. doi: 10.1016/j.chembiol.2017.11.006. [PMID: 29249695]
  • Joshua S Bryer, Katalin Susztak. Screening Drugs for Kidney Disease: Targeting the Podocyte. Cell chemical biology. 2018 02; 25(2):126-127. doi: 10.1016/j.chembiol.2018.01.018. [PMID: 29452609]
  • Ellen L Berg, Mark A Polokoff, Alison O'Mahony, Dat Nguyen, Xitong Li. Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. International journal of molecular sciences. 2015 Jan; 16(1):1008-29. doi: 10.3390/ijms16011008. [PMID: 25569083]
  • Bilin Chou, Ryan S Adler, Min Meng, Shaundel Percey, Brian Dean, Cornelis E C A Hop, Young G Shin. Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0879 and its metabolite in dog plasma using solid phase extraction. Journal of pharmaceutical and biomedical analysis. 2012 Nov; 70(?):354-61. doi: 10.1016/j.jpba.2012.05.029. [PMID: 22717139]
  • E F Choo, J P Driscoll, J Feng, B Liederer, E Plise, N Randolph, Y Shin, S Wong, Y Ran. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species. Xenobiotica; the fate of foreign compounds in biological systems. 2009 Sep; 39(9):700-9. doi: 10.1080/00498250902991827. [PMID: 19552528]
  • Harvey Wong, Marcia Belvin, Sylvia Herter, Klaus P Hoeflich, Lesley J Murray, Leo Wong, Edna F Choo. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. The Journal of pharmacology and experimental therapeutics. 2009 Apr; 329(1):360-7. doi: 10.1124/jpet.108.148189. [PMID: 19147858]